Rheumatology Journals

Rheumatology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Phung OJ et al. – Golimumab is a human anti–tumor necrosis factor (TNF)–alpha monoclonal antibody that was recently approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). In clinical trials, subcutaneous (SC) golimumab injected every 4 weeks significantly improved clinically relevant end points in all 3 disease states. Golimumab may increase the risk for upper respiratory tract infection, lymphoma, and injection–site reaction, but the incidence of these adverse events was low in clinical trials.


Today in Autoimmune/Heritable...keeping you current

Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögrens syndrome
Arthritis & Rheumatism, 11/06/09

Lung involvement in patients with primary Sjögrens syndrome: What are the predictors?
Rheumatology International, 10/26/09

A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis
Rheumatology, 10/23/09

Today in Clinical Pharmacology...keeping you current

Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09

Treatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/10/09

Osteoarthritis: A review of treatment options
Geriatrics, 10/21/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address